Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ECI
|
|||
| Former ID |
DIB010674
|
|||
| Drug Name |
TD-101
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Flavivirus infection [ICD-11: 1C80] | Phase 2 | [1] | |
| Pachyonychia [ICD-11: EE10.3; ICD-10: L60.2] | Phase 1 | [2] | ||
| Company |
Transderm
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Keratin 6A messenger RNA (KRT6A mRNA) | Target Info | . | [3] |
| WikiPathways | Ectoderm Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT00716014) Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita. U.S. National Institutes of Health. | |||
| REF 3 | First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb;18(2):442-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.